GetTopicDetailResponse(id=54f81338108, topicName=Onivyde, introduction=Onivyde, content=null, image=null, comments=4, allHits=1119, url=https://h5.medsci.cn/topic?id=13381, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=48141, tagList=[TagDto(tagId=48141, tagName=Onivyde)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2036816, encodeId=0eb02036816be, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, objectTitle=FDA授予伊立替康脂質(zhì)體（ONIVYDE）快速通道指定，用于轉(zhuǎn)移性胰腺癌的一線聯(lián)合治療, objectType=article, longId=196066, objectId=8dab1960666a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dab1960666a, replyNumber=0, likeNumber=87, createdTime=2020-09-05, rootId=0, userName=longerg, userId=2f8f432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dab1960666a, moduleTitle=FDA授予伊立替康脂質(zhì)體（ONIVYDE）快速通道指定，用于轉(zhuǎn)移性胰腺癌的一線聯(lián)合治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8dab1960666a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036815, encodeId=e1862036815e2, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, objectTitle=WCLC 2019：評(píng)估脂質(zhì)體伊立替康（ONIVYDE）作為小細(xì)胞肺癌的二線療法, objectType=article, longId=179176, objectId=99521e9176c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99521e9176c4, replyNumber=0, likeNumber=93, createdTime=2019-10-23, rootId=0, userName=longerg, userId=2f8f432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99521e9176c4, moduleTitle=WCLC 2019：評(píng)估脂質(zhì)體伊立替康（ONIVYDE）作為小細(xì)胞肺癌的二線療法, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=99521e9176c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036814, encodeId=0e80203681444, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, objectTitle=Shire胰腺癌藥物Onivyde慘遭英國(guó)NICE拒絕！, objectType=article, longId=94073, objectId=0c71940e386, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c71940e386, replyNumber=0, likeNumber=75, createdTime=2017-04-04, rootId=0, userName=longerg, userId=2f8f432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c71940e386, moduleTitle=Shire胰腺癌藥物Onivyde慘遭英國(guó)NICE拒絕！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0c71940e386)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2036813, encodeId=c5c02036813af, content=<a href='/topic/show?id=54f81338108' target=_blank style='color:#2F92EE;'>#Onivyde#</a>, objectTitle=Shire胰腺癌新藥Onivyde獲歐盟委員會(huì)批準(zhǔn), objectType=article, longId=80912, objectId=7f368091298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f368091298, replyNumber=0, likeNumber=104, createdTime=2017-04-06, rootId=0, userName=longerg, userId=2f8f432, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f368091298, moduleTitle=Shire胰腺癌新藥Onivyde獲歐盟委員會(huì)批準(zhǔn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7f368091298)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
